top of page

Quebec Pancreas Cancer Study

Clinicaltrials.gov ID

NCT04104230

Status

Recruiting

Study Type

Observational

Sponsor

George Zogopoulos

Start Date

March 11, 2012

Anticipated End Date

January 1, 2025

Study Contact

Name: Adeline Cuggia, MSc

Phone Number: 514-934-1934 ext 76333

Email: cancer.pancreas@mcgill.ca

About the Study

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

Conditions

  • Pancreas Cancer

  • Pancreatic Cancer

  • Pancreas Neoplasm

  • Pancreas Cyst

  • Pancreatic Precancerous Condition

  • Familial Pancreatic Cancer

  • Hereditary Cancer

  • Bile Duct Cancer

  • Ampullary Cancer

  • Duodenal Cancer

  • Gallbladder Cancer

Inclusion/Exclusion Criteria?

Primary, Secondary, Other Outcome Measures??

Locations in Canada

  • McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada

About the Study

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

Conditions

  • Pancreas Cancer

  • Pancreatic Cancer

  • Pancreas Neoplasm

  • Pancreas Cyst

  • Pancreatic Precancerous Condition

  • Familial Pancreatic Cancer

  • Hereditary Cancer

  • Bile Duct Cancer

  • Ampullary Cancer

  • Duodenal Cancer

  • Gallbladder Cancer

Interventions

n/a

Locations in Canada

  • McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada

  • Instagram
  • Facebook
  • Youtube
  • Twitter
logoImage.png
leaf-cihr-colour-en_edited.png

The Canadian Cholangiocarcinoma Collaborative (C3) is supported by a Canadian Cancer Society Breakthrough Team Grant in partnership with the Canadian Institutes of Health Research. The granting funds for C3 are managed by The Ottawa Hospital Research Institute, which serves as the lead institute for all collaborative operations.

© 2025 www.cholangio.ca. All rights reserved.

bottom of page